ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(0.83) by 5.68 percent. This is a 27.87 percent decrease over losses of $(0.61) per share from the same period last year.